Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/1039856219839471 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Vortioxetine in children and adolescents with major depressive disorder: 6-month and 18-month open-label, flexible-dose, long-term extension studies.
Eur Child Adolesc Psychiatry
September 2024
Clinical Research, H. Lundbeck A/S, Copenhagen, Denmark.
Children and adolescents with severe or relapsing major depressive disorder (MDD) may require long-term antidepressant use, but safety and tolerability data on long-term treatment are limited. In a randomized, placebo-controlled trial in children and another in adolescents, vortioxetine and placebo groups showed improvement in MDD symptoms without statistically significant differences between groups. To gain insights on long-term safety and tolerability of vortioxetine in pediatric patients, participants from these two studies were enrolled in two long-term extension studies: 6 months (NCT02871297) followed by another 18 months (NCT03108625).
View Article and Find Full Text PDFExploring vortioxetine combination with intranasal esketamine: A feasible alternative to SSRI/SNRI? - Insights from the REAL-ESK study.
J Affect Disord
December 2024
Department of Neurosciences, Imaging and Clinical Sciences, Università degli Studi G. D'Annunzio, Chieti, Italy.; Department of Mental Health, ASL 02 Lanciano-Vasto-Chieti, Chieti, Italy.
Article Synopsis
- Treatment-Resistant Depression (TRD) affects about 30% of people with Major Depressive Disorder, and a new nasal spray called Esketamine (ESK-NS) has been approved to help treat it when combined with certain medications.
- Researchers wanted to see if combining Vortioxetine, another antidepressant, with ESK-NS was just as good or better than the usual treatment.
- The results showed that the Vortioxetine and ESK-NS combo worked well to reduce depression and had fewer side effects, suggesting it could be a better option, but more research is needed to be sure.
Safety and effectiveness of vortioxetine in patients with major depressive disorder in a real-life clinical setting in India: results from an interventional, flexible-dose study.
Curr Med Res Opin
September 2024
H. Lundbeck A/S, Copenhagen, Denmark.
Objective: Vortioxetine has demonstrated safety and efficacy in improving symptoms of major depressive disorder (MDD), including overall functioning in real-world settings. This is the first study in a real-life clinical setting in India to evaluate effectiveness and safety of vortioxetine in patients with MDD.
Methods: This interventional, open-label study consisted of a 12-week treatment period with flexible doses of vortioxetine (5-20 mg/day) in adult patients (aged 18-65 years) with a confirmed MDD diagnosis.
Efficacy and safety of monoamine reuptake inhibitors in attention deficit hyperactivity disorder: A Bayesian network meta-analysis.
J Psychiatr Res
August 2024
Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Bhubaneswar, India. Electronic address:
The use of first-line drugs in clinical practice for attention deficit hyperactivity disorder (ADHD) is limited by their adverse effects. Many novel monoamine reuptake inhibitors (MRIs) with better safety profiles and comparable efficacy are also being tried for ADHD. This network meta-analysis (NMA) has evaluated the efficacy and safety of MRIs in ADHD.
View Article and Find Full Text PDFSwitching to Vortioxetine in Patients with Poorly Tolerated Antidepressant-Related Sexual Dysfunction in Clinical Practice: A 3-Month Prospective Real-Life Study.
J Clin Med
January 2024
Instituto de Investigación Biomédica de Salamanca (IBSAL), Paseo de San Vicente SN, 37007 Salamanca, Spain.
Unlabelled: Treatment-emergent sexual dysfunction (TESD) is one of the most frequent and persistent adverse effects of antidepressant medication. Sexual dysfunction (SD) secondary to SSRIs occurs in >60% of sexually active patients and >80% of healthy volunteers, with this causing treatment discontinuation in >35% of patients. However, this factor is rarely addressed in routine examinations, and only 15-30% of these events are spontaneously reported.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!